Dyslipidemia remains a central modifiable risk factor for cardiovascular disease, necessitating comprehensive and evolving management strategies. This review provides an updated overview of currently approved and emerging lipid-lowering therapies, focusing on their mechanisms of action, efficacy, and safety profiles. Traditional agents such as statins and bile acid sequestrants continue to play foundational roles, while newer therapies - including PCSK9 inhibitors, bempedoic acid, and RNA-based treatments - have expanded therapeutic options, particularly for high-risk or statin-intolerant patients. Additionally, therapies targeting triglyceride reduction, such as fibrates and omega-3 fatty acids, have demonstrated potential benefits in specific subgroups. Novel strategies such as gene editing, oral PCSK9 inhibitors, HDL-targeted treatments, and gut microbiota modulation represent promising future directions. The review also explores the utility of non-pharmacologic approaches, including lipid apheresis and bariatric surgery, in selected cases. Together, these developments highlight the importance of tailored, multi-targeted approaches to lipid management in the prevention of cardiovascular events. Continued research is essential to refine therapeutic algorithms and optimize patient outcomes.
D’ARRIGO et al. (Sun,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: